Your browser doesn't support javascript.
loading
SDHC Promoter Methylation, a Novel Pathogenic Mechanism in Parasympathetic Paragangliomas.
Bernardo-Castiñeira, Cristóbal; Valdés, Nuria; Sierra, Marta I; Sáenz-de-Santa-María, Inés; Bayón, Gustavo F; Perez, Raúl F; Fernández, Agustín F; Fraga, Mario F; Astudillo, Aurora; Menéndez, Rafael; Fernández, Belén; Del Olmo, Maribel; Suarez, Carlos; Chiara, María-Dolores.
Affiliation
  • Bernardo-Castiñeira C; Head and Neck Oncology Laboratory, Institute of Sanitary Research of Asturias (ISPA), Hospital Universitario Central de Asturias, Institute of Oncology of Asturias (IUOPA), CIBERONC, Oviedo, Spain.
  • Valdés N; Service of Endocrinology and Nutrition, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Sierra MI; Cancer Epigenetics Laboratory, Institute of Oncology of Asturias (IUOPA), Institute of Sanitary Research of Asturias (ISPA), Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Spain.
  • Sáenz-de-Santa-María I; Head and Neck Oncology Laboratory, Institute of Sanitary Research of Asturias (ISPA), Hospital Universitario Central de Asturias, Institute of Oncology of Asturias (IUOPA), CIBERONC, Oviedo, Spain.
  • Bayón GF; Cancer Epigenetics Laboratory, Institute of Oncology of Asturias (IUOPA), Institute of Sanitary Research of Asturias (ISPA), Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Spain.
  • Perez RF; Cancer Epigenetics Laboratory, Institute of Oncology of Asturias (IUOPA), Institute of Sanitary Research of Asturias (ISPA), Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Spain.
  • Fernández AF; Nanomaterials and Nanotechnology Research Center (CINN-CSIC), Universidad de Oviedo-Principado de Asturias, Oviedo, Spain.
  • Fraga MF; Cancer Epigenetics Laboratory, Institute of Oncology of Asturias (IUOPA), Institute of Sanitary Research of Asturias (ISPA), Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Spain.
  • Astudillo A; Nanomaterials and Nanotechnology Research Center (CINN-CSIC), Universidad de Oviedo-Principado de Asturias, Oviedo, Spain.
  • Menéndez R; Service of Pathology, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Fernández B; Service of Radiology, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Del Olmo M; Service of Nuclear Medicine, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Suarez C; Service of Endocrinology and Nutrition, Hospital Universitario la Fé, Valencia, Spain.
  • Chiara MD; Head and Neck Oncology Laboratory, Institute of Sanitary Research of Asturias (ISPA), Hospital Universitario Central de Asturias, Institute of Oncology of Asturias (IUOPA), CIBERONC, Oviedo, Spain.
J Clin Endocrinol Metab ; 103(1): 295-305, 2018 01 01.
Article in En | MEDLINE | ID: mdl-29126304
Context: Germline mutations in the succinate dehydrogenase A, B, C, and D genes (collectively, SDHx) predispose to the development of paragangliomas (PGLs) arising at the parasympathetic or sympathetic neuroendocrine systems. SDHx mutations cause absence of tumoral immunostaining for SDHB. However, negative SDHB immunostaining has also been found in a subset of PGLs that lack SDHx mutations. Settings: Here, we report the comprehensive molecular characterization of one such a tumor of parasympathetic origin compared with healthy paraganglia and other PGLs with or without SDHx mutations. Results: Integration of multiplatform data revealed somatic SDHC methylation and loss of the 1q23.3 region containing the SDHC gene. This correlated with decreased SDHC messenger RNA (mRNA) and protein levels. Furthermore, another genetic event found affected the VHL gene, which showed a decreased DNA copy number, associated with low VHL mRNA levels, and an absence of VHL protein detected by immunohistochemistry. In addition, the tumor displayed a pseudohypoxic phenotype consisting in overexpression of the hypoxia-inducible factor (HIF)-1α and miR-210, as well as downregulation of the iron-sulfur cluster assembly enzyme (ISCU) involved in SDHB maturation. This profile resembles that of SDHx- or VHL-mutated PGLs but not of PGLs with decreased VHL copy number, pointing to SDHC rather than VHL as the pathogenic driver. Conclusions: Collectively, these findings demonstrate the potential importance of both the SDHC epigenomic event and the activation of the HIF-1α/miR-210/ISCU axis in the pathogenesis of SDHx wild-type/SDHB-negative PGLs. To our knowledge, this is the first case of a sporadic parasympathetic PGL that carries silencing of SDHC, fulfilling the two-hit Knudson's model for tumorigenesis.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Paraganglioma / Biomarkers, Tumor / Promoter Regions, Genetic / DNA Methylation / Membrane Proteins / Mutation Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Clin Endocrinol Metab Year: 2018 Document type: Article Affiliation country: Spain Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Paraganglioma / Biomarkers, Tumor / Promoter Regions, Genetic / DNA Methylation / Membrane Proteins / Mutation Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Clin Endocrinol Metab Year: 2018 Document type: Article Affiliation country: Spain Country of publication: United States